Kyverna Therapeutics Inc.
09/25/2025 | Press release | Distributed by Public on 09/25/2025 14:06
Management Change/Compensation (Form 8-K)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 19, 2025, Steve Liapis, Ph.D. notified the board of directors (the "Board") of Kyverna Therapeutics, Inc. (the "Company") of his decision to resign from his position as a member of the Board and all committees thereof, effective September 30, 2025. Dr. Liapis' resignation is not due to any disagreement with the Company relating to any of the Company's operations, policies or practices.
The Board thanks Dr. Liapis for his years of service and valuable contributions to the Company.
Effective upon Dr. Liapis' resignation, the size of the Board will be reduced from eight to seven directors. The Board has appointed Christi Shaw, a current member of the Board, to the Audit Committee of the Board to fill the vacancy on the committee upon Dr. Liapis' resignation.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description |
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Kyverna Therapeutics Inc. published this content on September 25, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 25, 2025 at 20:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]